Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 3.9% of Immune Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Acerus Pharmaceuticals and Immune Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Acerus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Immune Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Acerus Pharmaceuticals | -254.66% | -346.72% | -94.54% |
Immune Pharmaceuticals | N/A | N/A | N/A |
Volatility and Risk
Acerus Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Earnings and Valuation
This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Acerus Pharmaceuticals | $7.38 million | 1.43 | $-18,790,000.00 | N/A | N/A |
Immune Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
Immune Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.
Summary
Immune Pharmaceuticals beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.